Results of Major Myeloma Treatment Trial Published in The Lancet
In December, the exciting results of the SWOG clinical trial on myeloma treatment, S0777, were published in The Lancet. The trial showed that the addition of the drug bortezomib to the standard two-drug course of dexamethasone and lenalidomide for multiple myeloma patients significantly lengthened the lives of impacted patients.
CRAB CEO and SWOG biostatistician, Antje Hoering, PhD, and CRAB and SWOG biostatistician, Rachael Sexton, MS, were instrumental in the design and analysis of this trial along with many other SWOG and CRAB personnel. CRAB contributed to the trial with statistical, data management, and technology support as a member of the SWOG Statistics and Data Management Center housed at the Fred Hutchinson Cancer Research Center and CRAB.
CRAB has long enjoyed a successful partnership with SWOG in clinical trial work, and looks forward to great collaborations in 2017. For more information about the publication in The Lancet, please see SWOG’s press release here.